The research activities of the IPPON consortium are at the forefront of integrated personalized cancer medicine. For different cancers in urgent need for improved therapeutic outcomes, our joint mission is:
- To develop novel and more effective therapeutic strategies;
- To improve the detection and understanding of mechanisms driving therapeutic resistance;
- To identify and validate biomarkers for early detection and personalized therapy.
The strong interdisciplinary partnership between basic, translational and clinical researchers within the IPPON consortium enables us to tackle burning research questions and clinical unmet needs, and leads us to meaningful advances in the highly innovative and rapidly changing field of personalized cancer medicine and to improved patient outcomes both in terms of survival and quality of life.
IPPON is always open to collaborations with public and non-public research institutes and companies in order to create more opportunities leading to improved cancer therapy. For more information you can always contact us.
Prof. dr. Jeroen Hendriks
Prof. dr. Filip Lardon
Prof. dr. Patrick Pauwels
Prof. dr. Evelien Smits
Prof. dr. Peter van Dam
Prof. dr. Wim Vanden Berghe
Prof. dr. Tim Van Den Wyngaert
Prof. dr. Sylvia Dewilde †
New high-impact publication on DNA methylation in T-ALL
Studie naar impact coronavirus bij kankerpatiënten
Book publication: Natural Products for Cancer Chemoprevention
This book discusses the efficacy of various naturally occurring chemopreventive agents in preventing or delaying cancer.